Abstract: The present invention provides monomeric and dimeric polypeptide fusions comprising mutated human ILT molecules and immunoglobulin Fc segments. Such compostions are useful, either alone or associated with a therapeutic agent, for targeting cells expressing Class I pMHC molecules.
Type:
Application
Filed:
November 8, 2007
Publication date:
June 3, 2010
Applicant:
MedGene Ltd.
Inventors:
Bent Karsten Jakobsen, Yi Li, Ruth Karen Moysey